S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NYSE:ENZ - Enzo Biochem Stock Price, Forecast & News

$2.53
+0.03 (+1.20 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$2.41
Now: $2.53
$2.57
50-Day Range
$1.82
MA: $2.42
$3.87
52-Week Range
$1.56
Now: $2.53
$4.85
Volume651,464 shs
Average Volume873,750 shs
Market Capitalization$120.32 million
P/E Ratio63.27
Dividend YieldN/A
Beta1.16
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing 'STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Read More
Enzo Biochem logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone212-583-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$81.17 million
Book Value$1.81 per share

Profitability

Net Income$2.49 million

Miscellaneous

Employees460
Market Cap$120.32 million
Next Earnings Date6/8/2020 (Estimated)
OptionableOptionable

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.


Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

How has Enzo Biochem's stock been impacted by COVID-19 (Coronavirus)?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENZ shares have decreased by 11.5% and is now trading at $2.53. View which stocks have been mosted impacted by Coronavirus.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Monday, June 8th 2020. View our earnings forecast for Enzo Biochem.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Thursday, March, 5th. The medical research company reported ($0.12) EPS for the quarter. The medical research company earned $19.38 million during the quarter. Enzo Biochem had a net margin of 1.92% and a negative return on equity of 31.31%. View Enzo Biochem's earnings history.

Has Enzo Biochem been receiving favorable news coverage?

Press coverage about ENZ stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enzo Biochem earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutEnzo Biochem.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,426,600 shares, an increase of 18.9% from the February 27th total of 1,200,000 shares. Based on an average trading volume of 579,900 shares, the days-to-cover ratio is currently 2.5 days. Currently, 3.3% of the company's shares are short sold. View Enzo Biochem's Current Options Chain.

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the following people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)
  • Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.53.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $120.32 million and generates $81.17 million in revenue each year. Enzo Biochem employs 460 workers across the globe. View additional information about Enzo Biochem.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is http://www.enzo.com/.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.


MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel